JP2002525060A5 - - Google Patents

Download PDF

Info

Publication number
JP2002525060A5
JP2002525060A5 JP2000570334A JP2000570334A JP2002525060A5 JP 2002525060 A5 JP2002525060 A5 JP 2002525060A5 JP 2000570334 A JP2000570334 A JP 2000570334A JP 2000570334 A JP2000570334 A JP 2000570334A JP 2002525060 A5 JP2002525060 A5 JP 2002525060A5
Authority
JP
Japan
Prior art keywords
opgl
polypeptide
nucleic acid
animal
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000570334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK1999/000481 external-priority patent/WO2000015807A1/en
Publication of JP2002525060A publication Critical patent/JP2002525060A/ja
Publication of JP2002525060A5 publication Critical patent/JP2002525060A5/ja
Pending legal-status Critical Current

Links

JP2000570334A 1998-09-15 1999-09-13 オステオプロテゲリンリガンド活性をダウンレギュレートする方法 Pending JP2002525060A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
US199801164 1998-10-02
US60/102,896 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (2)

Publication Number Publication Date
JP2002525060A JP2002525060A (ja) 2002-08-13
JP2002525060A5 true JP2002525060A5 (cg-RX-API-DMAC7.html) 2006-11-02

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000570334A Pending JP2002525060A (ja) 1998-09-15 1999-09-13 オステオプロテゲリンリガンド活性をダウンレギュレートする方法

Country Status (24)

Country Link
US (2) US6645500B1 (cg-RX-API-DMAC7.html)
EP (1) EP1114166B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525060A (cg-RX-API-DMAC7.html)
KR (1) KR100671036B1 (cg-RX-API-DMAC7.html)
CN (1) CN1318105A (cg-RX-API-DMAC7.html)
AT (1) ATE291628T1 (cg-RX-API-DMAC7.html)
AU (1) AU754971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2343654A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2001789A3 (cg-RX-API-DMAC7.html)
DE (1) DE69924392T2 (cg-RX-API-DMAC7.html)
EE (1) EE200100149A (cg-RX-API-DMAC7.html)
ES (1) ES2239457T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040261A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010188A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0103578A3 (cg-RX-API-DMAC7.html)
ID (1) ID28386A (cg-RX-API-DMAC7.html)
IL (2) IL141588A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011304L (cg-RX-API-DMAC7.html)
NZ (1) NZ510508A (cg-RX-API-DMAC7.html)
PL (1) PL196790B1 (cg-RX-API-DMAC7.html)
PT (1) PT1114166E (cg-RX-API-DMAC7.html)
SK (1) SK3062001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200100737T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000015807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2647796A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
TR201809678T4 (tr) * 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 tnf-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
US20250304708A1 (en) * 2022-09-07 2025-10-02 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Similar Documents

Publication Publication Date Title
Theisen et al. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli
CA2170236C (en) Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
CN108778322B (zh) 铜绿假单胞菌pcrv连接的抗原疫苗
JP4087898B2 (ja) 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン
KR860700090A (ko) 어드헤신(Adhesin)항원
JP3267333B2 (ja) 融合タンパク質
JPH03173830A (ja) ワクチン組成物
Dale et al. Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.
JP2003506325A5 (cg-RX-API-DMAC7.html)
TW202039587A (zh) 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
JPH08503602A (ja) 弱毒化細菌における組換え融合タンパク質の発現
HRP20010900A2 (en) Method for down-regulating gdf-8 activity
AU707083B2 (en) Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
ES2236718T3 (es) Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna.
Taubman et al. Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries
JP2006503017A5 (cg-RX-API-DMAC7.html)
EP0365646B1 (en) Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
US5824309A (en) Recombinant gas vesicles and uses thereof
WO1997020854A9 (en) Recombinant gas vesicles and uses thereof
ZA200302628B (en) Method for down-regulating IgE.
Kozuka et al. Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity
WO2004024183B1 (en) Immunization against autologous ghrelin
US20240139304A1 (en) P aeruginosa pcrv-linked antigen vaccines
JP2004529881A (ja) 合成ワクチン剤
US6602507B1 (en) Synthetic peptides from streptococcal M protein and vaccines prepared therefrom